Guodong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guodong Li has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Lixian Ding
Department of Vascular Surgery The First Affiliated Hospital of Fujian Medical University Fuzhou China
5 shared publicationsShuwei Dang
Department of General Surgery The Fourth Affiliated Hospital of Harbin Medical University Harbin China
5 shared publicationsJinxing Li
Department of General Surgery Harbin Fourth Hospital Harbin China
3 shared publications- Ming Liu
Department of General Surgery The Fourth Affiliated Hospital of Harbin Medical University Harbin China
3 shared publications Mingjun Sun
Department of General Surgery The Fourth Affiliated Hospital of Harbin Medical University Harbin China
3 shared publicationsYanyan Sun
Department of General Surgery The Fourth Affiliated Hospital of Harbin Medical University Harbin China
3 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (60) , e76963
METTL7A Downregulation Drives SLC1A5‐Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8 + T Cell Immunity in Gastric Cancer
Tumor metabolic dysregulation is a critical determinant of tumor progression and response to immunotherapy. Aberrant glutamine metabolism is a hallmark of gastric cancer (GC). However, beyond fueling GC cell anabolism, its role in remodeling the immunosuppressive tumor microenvironment remains poorly understood. Here, we show that GC cells overexpress solute carrier family 1 member 5 (SLC1A5) to drive glutamine accumulation, which not only promotes their own proliferation but also reduces glutamine availability to CD8 + T cells, thereby suppressing antitumor immunity. These dual effects cooperatively drive GC progression. Mechanistically, loss of methyltransferase‐like protein 7A (METTL7A) stabilizes SLC1A5 mRNA by reducing its m6A modification. Concurrently, METTL7A deficiency increased N‐glycosyltransferase β‐1,4‐galactosyltransferase 5 (B4GALT5) expression. B4GALT5 stabilizes SLC1A5 via N‐glycosylation at the N212 site, which blocks K48‐linked polyubiquitination and proteasomal degradation. We identify the natural flavonoid luteolin as an agent that upregulates METTL7A expression, which subsequently downregulates SLC1A5 expression and inhibits GC progression. Furthermore, luteolin significantly enhances the efficacy of anti‐PD‐1 therapy in GC. Collectively, our findings reveal that SLC1A5‐mediated glutamine competition drives both tumor cell proliferation and immune evasion in GC, and suggest that targeting the METTL7A/SLC1A5 axis may represent a promising therapeutic strategy.
- 3 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (60) , e76963
Open AccessMETTL7A Downregulation Drives SLC1A5‐Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8 + T Cell Immunity in Gastric Cancer
Tumor metabolic dysregulation is a critical determinant of tumor progression and response to immunotherapy. Aberrant glutamine metabolism is a hallmark of gastric cancer (GC). However, beyond fueling GC cell anabolism, its role in remodeling the immunosuppressive tumor microenvironment remains poorly understood. Here, we show that GC cells overexpress solute carrier family 1 member 5 (SLC1A5) to drive glutamine accumulation, which not only promotes their own proliferation but also reduces glutamine availability to CD8 + T cells, thereby suppressing antitumor immunity. These dual effects cooperatively drive GC progression. Mechanistically, loss of methyltransferase‐like protein 7A (METTL7A) stabilizes SLC1A5 mRNA by reducing its m6A modification. Concurrently, METTL7A deficiency increased N‐glycosyltransferase β‐1,4‐galactosyltransferase 5 (B4GALT5) expression. B4GALT5 stabilizes SLC1A5 via N‐glycosylation at the N212 site, which blocks K48‐linked polyubiquitination and proteasomal degradation. We identify the natural flavonoid luteolin as an agent that upregulates METTL7A expression, which subsequently downregulates SLC1A5 expression and inhibits GC progression. Furthermore, luteolin significantly enhances the efficacy of anti‐PD‐1 therapy in GC. Collectively, our findings reveal that SLC1A5‐mediated glutamine competition drives both tumor cell proliferation and immune evasion in GC, and suggest that targeting the METTL7A/SLC1A5 axis may represent a promising therapeutic strategy.
- 13 January 2026
- Published by Elsevier in Tissue and Cell
- Vol. 99, 103325
NFYA transcriptionally activates GPX4 inhibiting ferroptosis in colorectal cancer
- 13 January 2026
- Published by Elsevier in Tissue and Cell
- Vol. 99, 103325
NFYA transcriptionally activates GPX4 inhibiting ferroptosis in colorectal cancer
- Open Access
- 10 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (13) , e7424
MCM8 promotes gastric cancer progression through RPS15A and predicts poor prognosis
Background: Gastric cancer (GC) is the fourth leading cause of cancer‐related death worldwide. Minichromsome maintenance proteins family member 8 (MCM8) assists DNA repair and DNA replication. MCM8 exerts tumor promotor function in multiple digestive system tumors. MCM8 is also considered as a potential cancer therapeutic target.Methods: Bioinformatics methods were used to analyze MCM8 expression and clinicopathological significance. MCM8 expression was detected by immunohistochemistry (IHC) staining and qRT‐PCR. MCM8 functions in GC cell were explored by Celigo cell counting, colony formation, wound‐healing, transwell, and annexin V‐APC staining assays. The target of MCM8 was determined by human gene expression profile microarray. Human phospho‐kinase array kit evaluated changes in key proteins after ribosomal protein S15A (RPS15A) knockdown. MCM8 functions were reassessed in xenograft mouse model. IHC detected related proteins expression in mouse tumor sections.Results: MCM8 was significantly upregulated and predicted poor prognosis in GC. High expression of MCM8 was positively correlated with lymph node positive (p < 0.001), grade (p < 0.05), AJCC Stage (p < 0.001), pathologic T (p < 0.01), and pathologic N (p < 0.001). MCM8 knockdown inhibited proliferation, migration, and invasion while promoting apoptosis. RPS15A expression decreased significantly after MCM8 knockdown. It was also the only candidate target, which ranked among the top 10 downregulated differentially expressed genes (DEGs) in sh‐MCM8 group. RPS15A was identified as the target of MCM8 in GC. MCM8/RPS15A promoted phosphorylation of P38α, LYN, and p70S6K. Moreover, MCM8 knockdown inhibited tumor growth, RPS15A expression, and phosphorylation of P38α, LYN, and p70S6K in vivo.Conclusions: MCM8 is an oncogene and predicts poor prognosis in GC. MCM8/RPS15A facilitates GC progression.
- 10 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (13) , e7424
Open AccessMCM8 promotes gastric cancer progression through RPS15A and predicts poor prognosis
Background: Gastric cancer (GC) is the fourth leading cause of cancer‐related death worldwide. Minichromsome maintenance proteins family member 8 (MCM8) assists DNA repair and DNA replication. MCM8 exerts tumor promotor function in multiple digestive system tumors. MCM8 is also considered as a potential cancer therapeutic target.Methods: Bioinformatics methods were used to analyze MCM8 expression and clinicopathological significance. MCM8 expression was detected by immunohistochemistry (IHC) staining and qRT‐PCR. MCM8 functions in GC cell were explored by Celigo cell counting, colony formation, wound‐healing, transwell, and annexin V‐APC staining assays. The target of MCM8 was determined by human gene expression profile microarray. Human phospho‐kinase array kit evaluated changes in key proteins after ribosomal protein S15A (RPS15A) knockdown. MCM8 functions were reassessed in xenograft mouse model. IHC detected related proteins expression in mouse tumor sections.Results: MCM8 was significantly upregulated and predicted poor prognosis in GC. High expression of MCM8 was positively correlated with lymph node positive (p < 0.001), grade (p < 0.05), AJCC Stage (p < 0.001), pathologic T (p < 0.01), and pathologic N (p < 0.001). MCM8 knockdown inhibited proliferation, migration, and invasion while promoting apoptosis. RPS15A expression decreased significantly after MCM8 knockdown. It was also the only candidate target, which ranked among the top 10 downregulated differentially expressed genes (DEGs) in sh‐MCM8 group. RPS15A was identified as the target of MCM8 in GC. MCM8/RPS15A promoted phosphorylation of P38α, LYN, and p70S6K. Moreover, MCM8 knockdown inhibited tumor growth, RPS15A expression, and phosphorylation of P38α, LYN, and p70S6K in vivo.Conclusions: MCM8 is an oncogene and predicts poor prognosis in GC. MCM8/RPS15A facilitates GC progression.
- Top Cited Papers
- 6 January 2024
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 213, 150-163
Quercetin induces ferroptosis in gastric cancer cells by targeting SLC1A5 and regulating the p-Camk2/p-DRP1 and NRF2/GPX4 Axes
- 6 January 2024
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 213, 150-163
Top Cited PapersQuercetin induces ferroptosis in gastric cancer cells by targeting SLC1A5 and regulating the p-Camk2/p-DRP1 and NRF2/GPX4 Axes
- Open Access
- 1 January 2024
- Published by Wiley in International Journal of Genomics
- Vol. 2024 (1) , 9271183
The High‐Quality Genome Sequencing and Analysis of Red Raspberry (Rubus idaeus L.)
Red raspberry (Rubus idaeus L.), which is an important nutritional source for human health, belongs to fruit crops of the Rosaceae family. Here, we used Pacific Biosciences single‐molecule real‐time (SMRT) sequencing and high‐throughput chromosome conformation capture (Hi‐C) sequencing technologies to assemble genomes and reported a high‐quality Rubus idaeus L. (DNS‐1) genome with 321.29 Mb assembled into seven chromosomes. The LAI score of the DNS‐1 genome assembly was 21.32, belonging to gold quality. Approximately 52.3% of the assembly sequences were annotated as repetitive sequences, and 24.15% were composed of long terminal repeat elements. A total of 29,814 protein‐coding genes and 2474 pseudogenes were predicted in DNS‐1. We characterized the complete genomes of DNS‐1 and compared them to those of seven other species. We found that 652 gene families were unique to DNS‐1 and they were shaped from an ancestor. There were 1000 and 5193 gene families that expanded and contracted in the DNS‐1 genome. The Rubus idaeus L. genome can be used to understand the structure and evolution of Rosaceae genomes and can be developed to identify genes controlling important traits and improve breeding work.
- 1 January 2024
- Published by Wiley in International Journal of Genomics
- Vol. 2024 (1) , 9271183
Open AccessThe High‐Quality Genome Sequencing and Analysis of Red Raspberry (Rubus idaeus L.)
Red raspberry (Rubus idaeus L.), which is an important nutritional source for human health, belongs to fruit crops of the Rosaceae family. Here, we used Pacific Biosciences single‐molecule real‐time (SMRT) sequencing and high‐throughput chromosome conformation capture (Hi‐C) sequencing technologies to assemble genomes and reported a high‐quality Rubus idaeus L. (DNS‐1) genome with 321.29 Mb assembled into seven chromosomes. The LAI score of the DNS‐1 genome assembly was 21.32, belonging to gold quality. Approximately 52.3% of the assembly sequences were annotated as repetitive sequences, and 24.15% were composed of long terminal repeat elements. A total of 29,814 protein‐coding genes and 2474 pseudogenes were predicted in DNS‐1. We characterized the complete genomes of DNS‐1 and compared them to those of seven other species. We found that 652 gene families were unique to DNS‐1 and they were shaped from an ancestor. There were 1000 and 5193 gene families that expanded and contracted in the DNS‐1 genome. The Rubus idaeus L. genome can be used to understand the structure and evolution of Rosaceae genomes and can be developed to identify genes controlling important traits and improve breeding work.
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (1) , 387-402
KLF7 promotes colon adenocarcinoma progression through the PDGFB signaling pathway
Colon adenocarcinoma (COAD) is the most common malignancy of the digestive tract, which is characterized by a dismal prognosis. No effective treatment has been established presently, thus there is an urgent need to understand the mechanisms driving COAD progression in order to develop effective therapeutic approaches and enhance clinical outcomes. In this study, we found that KLF7 is overexpressed in COAD tissues and correlated with clinicopathological features of COAD. Both gain-of-function and loss-of-function experiments have unequivocally demonstrated that overexpression of KLF7 promotes the growth and metastasis of COAD in vitro and in vivo, while KLF7 knockdown attenuated these effects. Mechanistically, our findings reveal that KLF7 can specifically bind to the promoter region of PDGFB (TGGGTGGAG), thus promoting the transcription of PDGFB and increasing its secretion. Subsequently, secreted PDGFB facilitates the progression of COAD by activating MAPK/ERK, PI3K/AKT, and JAK/STAT3 signaling pathways through PDGFRβ. Additionally, we found that sunitinib can block PDGFB signaling and inhibit COAD progression, offering a promising therapeutic strategy for COAD treatment.
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (1) , 387-402
Open AccessKLF7 promotes colon adenocarcinoma progression through the PDGFB signaling pathway
Colon adenocarcinoma (COAD) is the most common malignancy of the digestive tract, which is characterized by a dismal prognosis. No effective treatment has been established presently, thus there is an urgent need to understand the mechanisms driving COAD progression in order to develop effective therapeutic approaches and enhance clinical outcomes. In this study, we found that KLF7 is overexpressed in COAD tissues and correlated with clinicopathological features of COAD. Both gain-of-function and loss-of-function experiments have unequivocally demonstrated that overexpression of KLF7 promotes the growth and metastasis of COAD in vitro and in vivo, while KLF7 knockdown attenuated these effects. Mechanistically, our findings reveal that KLF7 can specifically bind to the promoter region of PDGFB (TGGGTGGAG), thus promoting the transcription of PDGFB and increasing its secretion. Subsequently, secreted PDGFB facilitates the progression of COAD by activating MAPK/ERK, PI3K/AKT, and JAK/STAT3 signaling pathways through PDGFRβ. Additionally, we found that sunitinib can block PDGFB signaling and inhibit COAD progression, offering a promising therapeutic strategy for COAD treatment.
- 25 December 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 143, 107053
Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor
- 25 December 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 143, 107053
Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor
- Open Access
- 15 April 2020
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-14
KIF15 facilitates gastric cancer via enhancing proliferation, inhibiting apoptosis, and predict poor prognosis
Background: Kinesin superfamily proteins (KIFs) can transport membranous organelles and protein complexes in an ATP-dependent manner. Kinesin family member 15 (KIF15) is overexpressed in various cancers. However, the function of KIF15 in gastric cancer (GC) is still unclear. Methods: GC patients’ data from The Cancer Genome Atlas (TCGA) were analyzed by bioinformatics methods. The expression of KIF15 was examined in GC and paracarcinoma tissues from 41 patients to verify the analysis results. The relationship between KIF15 expression and clinical characteristics were also observed by bioinformatics methods. Kaplan–Meier survival analysis of 122 GC patients in our hospital was performed to explore the relationship between KIF15 expression levels and GC patients’ prognosis. KIF15 was downregulated in GC cell lines AGS and SGC-7901 by transfecting a lentivirus-mediated shRNA plasmid targeting KIF15. In vitro, GC cell proliferation and apoptosis were detected by MTT assay, colony formation assay, and Annexin V-APC staining. In vivo, xenograft experiments were used to verify the in vitro results. Furthermore, Human Apoptosis Antibody Array kit was used to screen possible targets of KIF15 in GC cell lines. Results: The bioinformatics results showed that KIF15 expression levels were higher in GC tissues than in normal tissues. IHC showed same results. High expression of KIF15 was statistical correlated with high age and early histologic stage. Kaplan–Meier curves indicated that high KIF15 expression predict poor prognosis in patients with GC. MTT assay and colony formation assay showed that KIF15 promote GC cell proliferation. Annexin V-APC staining found that KIF15 can inhibit GC cell apoptosis. Xenograft experiments reveal that downregulating KIF15 can inhibit GC tumor growth and promote GC apoptosis. Through detection of 43 anti-apoptotic proteins by the Human Apoptosis Antibody Array kit, it was confirmed that knocking down KIF15 can reduce seven anti-apoptotic proteins expression. Conclusions: Taken together, our study revealed a critical role for KIF15 to inhibit GC cell apoptosis and promote GC cell proliferation. KIF15 may decrease anti-apoptotic proteins expression by regulating apoptosis pathways. High expression of KIF15 predicts a poor prognosis in patients with GC. KIF15 might be a novel prognostic biomarker and a therapeutic target for GC.
- 15 April 2020
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-14
Open AccessKIF15 facilitates gastric cancer via enhancing proliferation, inhibiting apoptosis, and predict poor prognosis
Background: Kinesin superfamily proteins (KIFs) can transport membranous organelles and protein complexes in an ATP-dependent manner. Kinesin family member 15 (KIF15) is overexpressed in various cancers. However, the function of KIF15 in gastric cancer (GC) is still unclear. Methods: GC patients’ data from The Cancer Genome Atlas (TCGA) were analyzed by bioinformatics methods. The expression of KIF15 was examined in GC and paracarcinoma tissues from 41 patients to verify the analysis results. The relationship between KIF15 expression and clinical characteristics were also observed by bioinformatics methods. Kaplan–Meier survival analysis of 122 GC patients in our hospital was performed to explore the relationship between KIF15 expression levels and GC patients’ prognosis. KIF15 was downregulated in GC cell lines AGS and SGC-7901 by transfecting a lentivirus-mediated shRNA plasmid targeting KIF15. In vitro, GC cell proliferation and apoptosis were detected by MTT assay, colony formation assay, and Annexin V-APC staining. In vivo, xenograft experiments were used to verify the in vitro results. Furthermore, Human Apoptosis Antibody Array kit was used to screen possible targets of KIF15 in GC cell lines. Results: The bioinformatics results showed that KIF15 expression levels were higher in GC tissues than in normal tissues. IHC showed same results. High expression of KIF15 was statistical correlated with high age and early histologic stage. Kaplan–Meier curves indicated that high KIF15 expression predict poor prognosis in patients with GC. MTT assay and colony formation assay showed that KIF15 promote GC cell proliferation. Annexin V-APC staining found that KIF15 can inhibit GC cell apoptosis. Xenograft experiments reveal that downregulating KIF15 can inhibit GC tumor growth and promote GC apoptosis. Through detection of 43 anti-apoptotic proteins by the Human Apoptosis Antibody Array kit, it was confirmed that knocking down KIF15 can reduce seven anti-apoptotic proteins expression. Conclusions: Taken together, our study revealed a critical role for KIF15 to inhibit GC cell apoptosis and promote GC cell proliferation. KIF15 may decrease anti-apoptotic proteins expression by regulating apoptosis pathways. High expression of KIF15 predicts a poor prognosis in patients with GC. KIF15 might be a novel prognostic biomarker and a therapeutic target for GC.
- Open Access
- 28 March 2019
- Published by Springer Nature in Molecular Cancer
- Vol. 18 (1) , 1-11
Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4
Circular RNAs (circRNAs) are a novel type of noncoding RNAs and play important roles in tumorigenesis, including gastric cancer (GC). However, the functions of most circRNAs remain poorly understood. In our study, we aimed to investigate the functions of a new circRNA circ-DONSON in GC progression. The expression of circ-DONSON in gastric cancer tissues and adjacent normal tissues was analyzed by bioinformatics method, qRT-PCR, Northern blotting and in situ hybridization (ISH). The effects of circ-DONSON on GC cell proliferation, apoptosis, migration and invasion were measured by using CCK8, colony formation, EdU, immunofluorescence (IF), FACS and Transwell assays. qRT-PCR and Western blotting were utilized to validate how circ-DONSON regulates SOX4 expression. ChIP, DNA fluorescence in situ hybridization (DNA-FISH) and DNA accessibility assays were used to investigate how circ-DONSON regulates SOX4 transcription. The interaction between circ-DONSON and NURF complex was evaluated by mass spectrum, RNA immunoprecipitation (RIP), pulldown and EMSA assays. Xenograft mouse model was used to analyze the effect of circ-DONSON on GC growth in vivo. Elevated expression of circ-DONSON was observed in GC tissues and positively associated with advanced TNM stage and unfavorable prognosis. Silencing of circ-DONSON significantly suppressed the proliferation, migration and invasion of GC cells while promoting apoptosis. circ-DONSON was localized in the nucleus, recruited the NURF complex to SOX4 promoter and initiated its transcription. Silencing of the NURF complex subunit SNF2L, BPTF or RBBP4 similarly attenuated GC cell growth and increased apoptosis. circ-DONSON knockdown inhibited GC growth in vivo. circ-DONSON promotes GC progression through recruiting the NURF complex to initiate SOX4 expression.
- 28 March 2019
- Published by Springer Nature in Molecular Cancer
- Vol. 18 (1) , 1-11
Open AccessCircular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4
Circular RNAs (circRNAs) are a novel type of noncoding RNAs and play important roles in tumorigenesis, including gastric cancer (GC). However, the functions of most circRNAs remain poorly understood. In our study, we aimed to investigate the functions of a new circRNA circ-DONSON in GC progression. The expression of circ-DONSON in gastric cancer tissues and adjacent normal tissues was analyzed by bioinformatics method, qRT-PCR, Northern blotting and in situ hybridization (ISH). The effects of circ-DONSON on GC cell proliferation, apoptosis, migration and invasion were measured by using CCK8, colony formation, EdU, immunofluorescence (IF), FACS and Transwell assays. qRT-PCR and Western blotting were utilized to validate how circ-DONSON regulates SOX4 expression. ChIP, DNA fluorescence in situ hybridization (DNA-FISH) and DNA accessibility assays were used to investigate how circ-DONSON regulates SOX4 transcription. The interaction between circ-DONSON and NURF complex was evaluated by mass spectrum, RNA immunoprecipitation (RIP), pulldown and EMSA assays. Xenograft mouse model was used to analyze the effect of circ-DONSON on GC growth in vivo. Elevated expression of circ-DONSON was observed in GC tissues and positively associated with advanced TNM stage and unfavorable prognosis. Silencing of circ-DONSON significantly suppressed the proliferation, migration and invasion of GC cells while promoting apoptosis. circ-DONSON was localized in the nucleus, recruited the NURF complex to SOX4 promoter and initiated its transcription. Silencing of the NURF complex subunit SNF2L, BPTF or RBBP4 similarly attenuated GC cell growth and increased apoptosis. circ-DONSON knockdown inhibited GC growth in vivo. circ-DONSON promotes GC progression through recruiting the NURF complex to initiate SOX4 expression.
- Open Access
- 1 January 2016
- Published by Wiley in Disease Markers
- Vol. 2016, 1-7
Discovery and Validation of Hypermethylated Markers for Colorectal Cancer
Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2andAKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves ofADD2andAKR1B1are higher than that ofSEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation ofADD2andAKR1B1could be potential screening markers of CRC.
- 1 January 2016
- Published by Wiley in Disease Markers
- Vol. 2016, 1-7
Open AccessDiscovery and Validation of Hypermethylated Markers for Colorectal Cancer
Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2andAKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves ofADD2andAKR1B1are higher than that ofSEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation ofADD2andAKR1B1could be potential screening markers of CRC.